Appointment sheet
Conjunctival melanoma
Prepared with OnCo (onco.cc/prep/conjunctival-melanoma/). Orientation, not medical advice; your team knows your case.
My details
Name
Date of appointment
Hospital and clinician
Who is coming with me
What I know, what is unclear, changes to discuss
Saved in this browserWhat I know so far
What is unclear to me
Changes since last time
My questions
10 on the sheetNewly diagnosed
- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example BRAF V600E, NRAS and NF1 mutations, Tumour origin and location, Tumour thickness and ulceration, Sentinel node status in selected cases), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
Localised
- 5.For my situation (localised), which of the standard options do you recommend and why?
- 6.Am I a candidate for Mitomycin C, and what side effects should I expect?
Metastatic
- 7.For my situation (metastatic), which of the standard options do you recommend and why?
- 8.Am I a candidate for Dabrafenib, Trametinib, Nivolumab or related drugs, and what side effects should I expect?
Any stage
- 9.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 10.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: BRAF V600E (about 35 percent), NRAS and NF1 mutations, Tumour origin and location (bulbar versus non-bulbar), Tumour thickness and ulceration, Sentinel node status in selected cases.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Localised: No-touch excision with cryotherapy to the margins and topical mitomycin or interferon for associated melanosis; sentinel node biopsy in selected cases. (Melanoma, Mitomycin C)
- Metastatic: Treated as on the melanoma page: BRAF and MEK inhibitors when mutated, checkpoint inhibitors otherwise. (Melanoma, Dabrafenib, Trametinib, Nivolumab, Pembrolizumab)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.
Answers and next steps
Saved in this browserWhat I was told
Agreed next steps, dates and who to call